# Lord's Mark AI breast cancer screening nears clinical trials

> Lord's Mark's AI-powered radiation-free breast cancer screening technology advances to final clinical trials across global markets.
- Title: Lord's Mark AI breast cancer screening nears clinical trials
- Summary: Lord's Mark's AI-powered radiation-free breast cancer screening technology advances to final clinical trials across global markets. Lord's Mark Industries…
- Keywords: lord's mark industries limited, c-met, ai breast cancer screening, phase 2 trials, clinical trials, breast cancer diagnostics, radiation-free screening, india, great britain, cdsco, Lord's, Mark
- Source: The Economic Times — https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/lords-mark-advances-ai-breast-cancer-screening-towards-clinical-trials/articleshow/134482696.cms
- Author: Spotlight Wire
- Published: 2026-09-25T11:00:00+00:00
- Read time: 1 min
- Topics: lord's mark industries limited, c-met, ai breast cancer screening, phase 2 trials, clinical trials, breast cancer diagnostics, radiation-free screening, india, us, eu, great britain, cdsco
## AI breast cancer screening technology
Lord's Mark Industries Limited has progressed its AI-powered radiation-free wearable breast cancer screening technology towards final clinical trials.
## Global clinical trial plans
Trials will begin in india, the usa, europe, and great britain starting january 2027 for 98% accuracy cell-level cancer detection.
## Market context
Breast cancer affects 2.4 million women globally with 694,000 deaths in 2024, driving a $5.9 billion diagnostics market projected to reach $11.4 billion by 2033.
## Technology approach
The wearable uses high-precision thermal sensors and ai-based temperature mapping to detect abnormalities without radiation.
## Regulatory progress
The technology has completed clinical trials in india and is targeting cdsc approval in india and regulatory pathways in the us and europe by march 2027.
## Commercial timeline
Lord's Mark plans to commercialize the product by april 2027 after successful clinical validation and regulatory approvals.
## Healthcare access goals
The company seeks integration into national screening programs and insurance frameworks to improve affordability and accessibility globally.
## Key takeaway

Lord's Mark Industries Limited's AI breast cancer screening technology will begin phase 2 trials in 2027 targeting 98% accuracy for early detection.